International Journal of Cancer最新文献_第10页

Comments on “Associations of plasma omega-6 and omega-3 fatty acids with overall and 19 site-specific cancers: A population-based cohort study in UK Biobank” 对“血浆omega-6和omega-3脂肪酸与整体和19个部位特异性癌症的关联：英国生物银行的一项基于人群的队列研究”的评论。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-20 DOI: 10.1002/ijc.35333

Tomoyuki Kawada

引用次数: 0

Long-term use of low-dose aspirin for cancer prevention: A 20-year longitudinal cohort study of 1,506,525 Hong Kong residents. 长期使用低剂量阿司匹林预防癌症：一项针对1,506,525名香港居民的20年纵向队列研究。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-18 DOI: 10.1002/ijc.35331

Amy Lam, Ziyu Hao, Karen Yiu, Stephen Chan, Francis Chan, Joseph Sung, Kelvin Tsoi

{"title":"Long-term use of low-dose aspirin for cancer prevention: A 20-year longitudinal cohort study of 1,506,525 Hong Kong residents.","authors":"Amy Lam, Ziyu Hao, Karen Yiu, Stephen Chan, Francis Chan, Joseph Sung, Kelvin Tsoi","doi":"10.1002/ijc.35331","DOIUrl":"https://doi.org/10.1002/ijc.35331","url":null,"abstract":"Long-term use of low-dose aspirin has been demonstrated to reduce cancer risk, but the duration of necessary medication use remains uncertain. This study aimed to investigate the long-term chemoprotective effect of aspirin among the Chinese population. This population-based study included all aspirin users between 2000 and 2019. Aspirin users were age-sex matched with non-users at a 1:2 ratio. Cancer incidence and mortality were the main outcomes measured. Survival analyses with the Fine-Gray modelling were performed. The chemoprotective effects were measured by the sub-distribution hazard ratios (SHR) with control for the competing risks. A total of 538,147 aspirin users and 968,378 non-users were included, with a mean age of 64.8 years, 9,543,399 person-years of follow-up and 90% of users with 80 mg aspirin. The long-term use of aspirin was associated with a reduced risk of cancer (SHR 0.92, 95% CI 0.91-0.94) and a reduced risk of cancer mortality (SHR 0.80, 95% CI 0.79-0.82). Stronger chemopreventive effects were observed among those who used aspirin for more than 10 years, including risk reductions for lung (SHR 0.56, 95% CI 0.51-0.60), breast (SHR 0.34, 95% CI 0.29-0.38) and colorectal (SHR 0.37, 95% CI 0.33-0.40) cancers, but not for bladder cancer and leukaemia. Low-dose use of aspirin was associated with lower risk of cancer among Chinese. The association was even stronger for those using aspirin for more than 10 years. Prescription of aspirin may be started as early as at age of 40, as the chemoprotective effect also applied for early cancers.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142996372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial. 安洛替尼联合吉西他滨和顺铂作为复发或转移性鼻咽癌一线治疗的疗效和安全性：一项单臂临床试验

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-18 DOI: 10.1002/ijc.35340

Zhehao Xiao, Weiling Chen, Youqin Du, Fanyan Zeng, Fang Su, Shiting Huang, Song Qu

{"title":"Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial.","authors":"Zhehao Xiao, Weiling Chen, Youqin Du, Fanyan Zeng, Fang Su, Shiting Huang, Song Qu","doi":"10.1002/ijc.35340","DOIUrl":"https://doi.org/10.1002/ijc.35340","url":null,"abstract":"The effectiveness and safety of combining anlotinib with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) have not been definitively established. This research seeks to investigate the potential benefits and risks of utilizing this combination therapy in the first-line management of R/M NPC. The research involved 22 individuals diagnosed with R/M NPC and who had not undergone any previous treatment. These patients were administered a concomitant therapy of anlotinib, gemcitabine, and cisplatin in cycles occurring every 3 weeks. The primary focus of the study was to assess progression-free survival (PFS), while secondary endpoints included overall survival (OS), disease control rate (DCR), and objective response rate (ORR). The findings revealed that the median PFS duration for patients with R/M NPC receiving the GPA regimen as a first-line treatment was 12.6 months, with a 95% confidence interval (CI): 0.1 to 25.2. The median OS was reported as 37.4 months, with 95% CI: 28.0 to 46.8. The DCR in this study was 95.5%, while the ORR was 63.6%. Anlotinib has demonstrated a degree of effectiveness in the initial treatment of R/M NPC, while maintaining an acceptable level of safety.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pancreatic stellate cell: Update on molecular investigations and clinical translation in pancreatic cancer 胰腺星状细胞：胰腺癌分子研究和临床转化的最新进展。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-18 DOI: 10.1002/ijc.35326

Yawei Liu, Ran Xue

引用次数: 0

Inequalities in relative cancer survival by race, immigration status, income, and education for 22 cancer sites in Canada, a cohort study. 加拿大22个癌症站点的种族、移民身份、收入和教育的相对癌症生存不平等，一项队列研究。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-16 DOI: 10.1002/ijc.35337

Talía Malagón, Sarah Botting-Provost, Alissa Moore, Mariam El-Zein, Eduardo L Franco

{"title":"Inequalities in relative cancer survival by race, immigration status, income, and education for 22 cancer sites in Canada, a cohort study.","authors":"Talía Malagón, Sarah Botting-Provost, Alissa Moore, Mariam El-Zein, Eduardo L Franco","doi":"10.1002/ijc.35337","DOIUrl":"https://doi.org/10.1002/ijc.35337","url":null,"abstract":"There is a paucity of disaggregated data to monitor cancer health inequalities in Canada. We used data linkage to estimate site-specific cancer relative survival by race, immigration status, household income, and education level in Canada. We pooled the Canadian Census Health and Environment Cohorts, which are linked datasets of 5.9 million respondents of the 2006 long-form census and 6.5 million respondents of the 2011 National Household Survey. Individual-level respondent data from these surveys were probabilistically linked with the Canadian Cancer Registry up to 2015 and with the Canadian Vital Statistics Death database up to 2019. We used propensity score matching and Poisson models to calculate age-standardized relative survival by equity stratifiers for all cancers combined and for 22 individual cancer sites for the period 2006-2019. There were 560,905 primary cancer cases diagnosed over follow-up included in survival analyses; the age-standardized period relative survival was 72.9% at 5 years post-diagnosis. 5-year relative survival was higher in immigrants (74.1%, 95%CI 73.8-74.4) than in Canadian-born persons (69.6%, 95%CI 69.4-69.8), and higher in racial groups with high proportions of immigrants. There was a marked socioeconomic gradient, with 11%-12% lower relative survival in cancer patients in the lowest household income and education levels than in the highest levels. Socioeconomic gradients were observed for most cancer sites, though the magnitude varied by site. The observed differences in relative survival suggest there remain important inequities in cancer control and care delivery and quality even in a universal healthcare system.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Childhood vaccinations and the risk of leukemia: A nationwide cohort study. 儿童接种疫苗与白血病风险：一项全国性队列研究。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-16 DOI: 10.1002/ijc.35338

Aya Alberts, Susanne K Kjaer, Signe H Søegaard, Jeanette F Winther, Kjeld Schmiegelow, Liza Sopina, Friederike Erdmann, Marie Hargreave

{"title":"Childhood vaccinations and the risk of leukemia: A nationwide cohort study.","authors":"Aya Alberts, Susanne K Kjaer, Signe H Søegaard, Jeanette F Winther, Kjeld Schmiegelow, Liza Sopina, Friederike Erdmann, Marie Hargreave","doi":"10.1002/ijc.35338","DOIUrl":"https://doi.org/10.1002/ijc.35338","url":null,"abstract":"A protective effect of childhood vaccinations on leukemia risk, particularly acute lymphoblastic leukemia (ALL), has been hypothesized, though findings are inconsistent. We used a nationwide cohort of Danish children born 1997-2018 (n = 1,360,230), to examine associations between childhood vaccinations and leukemia (<20 years) using registry data (follow-up: December 31, 2018). Cox proportional hazard models with age as the underlying time estimated hazard ratios (HRs) for leukemia (any, ALL, acute myeloid [AML], and other), comparing vaccinated with unvaccinated children. We also accessed the effect of each additional vaccine dose. During 14,536,819 person-years, 771 children were diagnosed with leukemia (74% ALL, 16% AML, and 10% other). Any vaccination was associated with an increased HR for ALL (HR: 2.76; 95% CI: 0.66-11.58), compared to unvaccinated children, with a change in HR of 1.01 (95% CI: 0.96-1.05) per dose. The corresponding HRs for any leukemia, AML, and other leukemia were 1.04 (95% CI: 0.50-2.17), 0.67 (95% CI: 0.18-2.59) and 0.29 (95% CI: 0.09-0.99), with a change in HR of 0.97 (95% CI: 0.94-1.02), 0.92 (95% CI: 0.84-1.00, p = .062) and 0.88 (95% CI: 0.78-1.00, p = .044) per dose. No significant associations were found for vaccination types, except for the pneumococcal vaccine which was associated with a decreased risk of other leukemia (HR: 0.32; 95% CI: 0.14-0.74). In six-months lag analyses, no significant associations were observed, and decreased risks were attenuated. The results provide no strong evidence that childhood vaccinations reduce leukemia risk. The limited number of unvaccinated cases and wide confidence intervals suggest cautious interpretation of some findings.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142997075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022. 中东和北非地区目前和未来女性乳腺癌负担（使用GLOBOCAN 2022的估计数据）

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-10 DOI: 10.1002/ijc.35325

Mariam Zahwe, Karima Bendahhou, Sultan Eser, Deborah Mukherji, Heba Fouad, Ibtihal Fadhil, Isabelle Soerjomataram, Ariana Znaor

{"title":"Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022.","authors":"Mariam Zahwe, Karima Bendahhou, Sultan Eser, Deborah Mukherji, Heba Fouad, Ibtihal Fadhil, Isabelle Soerjomataram, Ariana Znaor","doi":"10.1002/ijc.35325","DOIUrl":"10.1002/ijc.35325","url":null,"abstract":"Breast cancer is the most diagnosed female cancer and the most common cause of cancer death in women in the Middle East and North Africa (MENA) region. In this study, we aimed to describe the current patterns of breast cancer among women in the MENA region and estimate the burden for the year 2050. We used the estimates of the breast cancer incidence and mortality from the GLOBOCAN 2022 database and predicted the burden of breast cancer in 2050 according to different scenarios. With 118,200 new breast cancer cases and 41,000 deaths, breast cancer contributed to 25% of cancer incidence and almost 20% of cancer mortality among women in MENA. The highest incidence rates were in Algeria and Iraq (≥60/100,000) and the lowest rates in Saudi Arabia and Yemen (<30/100,000). The highest mortality rates were in Iraq, Syrian Arab Republic, Algeria, and Sudan (>20/100,000), and the lowest in Saudi Arabia (7.6/100,000). While the incidence rates were low compared to other world regions, the mortality rates (16.9/100,000) were higher than in any other world region except Sub-Saharan Africa. The incidence rates for women <50 years in MENA were 5.5 times lower than in women aged ≥50 years, and lower than for women <50 years in Western countries. By 2050, the burden of breast cancer is estimated to increase to 219,000 new cases and to 88,900 deaths (86% and 117%, respectively). Scaling up cancer control to curb the rising burden alongside improved surveillance is vital to develop targeted interventions and improving outcomes.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study 晚期食管癌或胃癌患者放弃全身治疗的考虑：一项真实世界的证据研究

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-09 DOI: 10.1002/ijc.35314

Ellis Slotman, Marieke Pape, Hanneke W. M. van Laarhoven, Roos E. Pouw, Yvette M. van der Linden, Rob H. A. Verhoeven, Sabine Siesling, Heidi P. Fransen, Natasja J. H. Raijmakers

{"title":"Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study","authors":"Ellis Slotman, Marieke Pape, Hanneke W. M. van Laarhoven, Roos E. Pouw, Yvette M. van der Linden, Rob H. A. Verhoeven, Sabine Siesling, Heidi P. Fransen, Natasja J. H. Raijmakers","doi":"10.1002/ijc.35314","DOIUrl":"10.1002/ijc.35314","url":null,"abstract":"The majority of patients with advanced esophageal or gastric cancer do not start palliative systemic treatment. To gain insight into the considerations underlying the decision not to start systemic treatment, we analyzed characteristics of patients starting and not starting systemic treatment, reasons for not starting systemic treatment, and receipt of local palliative treatments on a nationwide scale. Patients diagnosed with advanced esophageal or gastric cancer between 2015 and 2021 were included (n = 10,948). Survival was compared using propensity score matching on patient and disease characteristics. Most patients did not start systemic treatment (esophageal cancer 59%; gastric cancer 64%). These patients were generally older, more often female, had more comorbidities and a worse performance status. The main reason for not starting systemic treatment was patient or family preference (35%). Among patients who did not start systemic treatment, 47% (esophageal) and 19% (gastric), received local palliative treatment, most commonly radiotherapy. Patients who did not start systemic treatment had worse median overall survival compared to patients who did start (esophageal cancer 2.9 months vs. 8.9 months; gastric cancer 2.2 vs. 8.2 months). These findings indicate that patient condition and disease burden are important aspects in systemic treatment decisions. However, patient or family preference was the main reason for not starting systemic treatment, highlighting that their priorities also strongly influence the decision. Systemic treatment did show to be associated with improved overall survival in matched patients, and therefore adequately weighing treatment risks and benefits based on real world data against patient preferences is of utmost importance.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 10","pages":"1950-1960"},"PeriodicalIF":5.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estrogen, estrogen receptor and the tumor microenvironment of NSCLC 雌激素、雌激素受体与非小细胞肺癌的肿瘤微环境。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-03 DOI: 10.1002/ijc.35309

Mingxin Diao, Yangwei Wang, Shihao Wu, Shiwen He, Yongde Liao

{"title":"Estrogen, estrogen receptor and the tumor microenvironment of NSCLC","authors":"Mingxin Diao, Yangwei Wang, Shihao Wu, Shiwen He, Yongde Liao","doi":"10.1002/ijc.35309","DOIUrl":"10.1002/ijc.35309","url":null,"abstract":"Lung cancer remains the foremost cause of cancer-related mortality worldwide. Clinical observations reveal a notable increase in both the proportion and mortality rate among female non-small cell lung cancer (NSCLC) patients compared to males, a trend that continues to escalate. Extensive preclinical research underscores the pivotal role of estrogen in the initiation, progression, prognosis, and treatment response of NSCLC. Estrogen receptors are widely expressed in stromal and immune cells, influencing cellular activities across innate and adaptive immune systems. Immune evasion mechanisms significantly impact tumor development and outcomes, with immunotherapy offering promise in NSCLC by targeting these mechanisms. The intriguing gender disparities in immunotherapy responses prompt an exploration into the data on NSCLC occurrence, progression, and gender-specific immunotherapy. Evidence highlights estrogen's contribution to a tumor-permissive microenvironment, influencing various cells including cancer-associated fibroblasts, macrophages, neutrophils, dendritic cells, natural killer cells, B cells, and T cells. Gender-specific variations in NSCLC occurrence, development, prognosis, and treatment efficacy likely stem from interactions between estrogen, lung cancer cells, and these estrogen-responsive cells, shaping a microenvironment conducive to tumor progression. Clarifying estrogen's role and its signaling pathways in NSCLC may unveil novel therapeutic strategies to modify the tumor microenvironment or enhance immunotherapy efficacy.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 8","pages":"1501-1508"},"PeriodicalIF":5.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142925941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neo-enhancers in T-cell acute lymphoblastic Leukaemia (T-ALL) and beyond. t细胞急性淋巴细胞白血病（T-ALL）及其他疾病的新增强剂。

IF 5.7 2区医学

International Journal of Cancer Pub Date : 2025-01-03 DOI: 10.1002/ijc.35315

Charlotte Smith, Vahid Asnafi, Aurore Touzart

引用次数: 0